Keith Katkin bought $91k of SNDX
director at Syndax Pharmaceuticals Inc. 10,000 shares at an average of $9.11, traded May 19, 2025, filed May 19, 2025.
Score components
- +15RoleDirector
- +9Trade size$91k at market
- +3Relative to holdingsHoldings up 11%
- +18Price context4% above the 52-week low; 57% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-074289, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2025 | POpen-market purchase Common Stock | +10,000 | $9.11 | $91k | 100,000 | May 19, 2025 |
Related signals
Other insiders at Syndax Pharmaceuticals Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Syndax Pharmaceuticals Inc | Nicholas A.J. Botwood Head of R&D, CMO | $1.2M 65,515 shares | -69% | |
| 38Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $72k 3,410 shares | -2% | |
| 48Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $361k 17,159 shares | -3% | |
| 36Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $43k 2,082 shares | -1% | |
| 44Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $153k 7,412 shares | -1% | |
| 25Weak | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $2.6M 157,307 shares | -34% | |
| 13Weak | Syndax Pharmaceuticals Inc | Dennis Podlesak director | $875k 57,600 shares | -27% | |
| 30Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $12k 1,296 shares | -1% | |
| 41Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $70k 7,534 shares | -2% | |
| 68Notable | Syndax Pharmaceuticals Inc | Nicholas A.J. Botwood Head of R&D, CMO | $106k 11,765 shares | +50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.